Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning

  • M. L. Sorror
  • R. Storb
Conference paper
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 11)


Chronic Myeloid Leukemia Hematopoietic Cell Transplantation Allogeneic Hematopoietic Cell Transplantation Nonmyeloablative Conditioning Full Donor Chimerism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anagnostopoulos A, de Lima M, Munsell M, Shahjahan M, Couriel D, Martin T, Cano P, McMannis, Gajewski J, Anderson B, Champlin R, Giralt S (2002) Unrelated donor bone marrow transplantation (UDR) for adults with AML/MDS: similar outcomes with ablative or reduced intensity preparative regimens (RIPR) (abstract). Blood 100 (Part 1):635a, 2502CrossRefGoogle Scholar
  2. Anderlini P, Acholonu S, Okoroji GJ, Giralt S, Ueno N, Donato M, Andersson BS, Khouri I, Couriel D, Ippoliti C, Valverde RB, Champlin RE (2002) Reduced early transplant-related mortality following allogeneic stem cell transplantation (SCT) with fludarabine-based, reduced-intensity conditioning from matched related and unrelated donors in advanced Hodgkin’s disease (HD) (abstract). Blood 100 (Part 1):620a, 2444Google Scholar
  3. Atkinson K (ed) (2000) Clinical bone marrow and blood stem cell transplantation. Cambridge University Press, Cambridge, UKGoogle Scholar
  4. Barnes DWH, Corp MJ, Loutit JF, Neal FE (1956) Treatment of murine leukaemia with x-rays and homologous bone marrow. Preliminary communication. Br Med J 2:626–627CrossRefPubMedGoogle Scholar
  5. Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW, Fisher DR, Sandmaier BM (2003) Selective T-cell ablation with bismuth-213 labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 101:5068–5075PubMedCrossRefGoogle Scholar
  6. Bornhauser M, Thiede C, Platzbecker U, Jenke A, Helwig A, Plettig R, Freiberg-Richter J, Rollig C, Geissler G, Lutterbeck K, Oelschlagel U, Ehninger G (2001) Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 7:2254–2262PubMedGoogle Scholar
  7. Burchenal JH, Oettgen HF, Holmberg EAD, Hemphill SC, Reppert JA (1960) Effect of total body irradiation on the transplantability of mouse leukemias. Cancer Res 20:425–430PubMedGoogle Scholar
  8. Carvallo C, Geller N, Kurlander R, Srinivasan R, Mena O, Igarashi T, Griffith LM, Linehan WM, Childs RW (2004) Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors. Blood 103:1560–1563PubMedCrossRefGoogle Scholar
  9. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, Geary J, Thuraisundaram D, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99:1071–1078PubMedCrossRefGoogle Scholar
  10. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, Read EJ, Carter C, Bahceci E, Young NS, Barrett AJ (1999) Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell trans-plantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94:3234–3241PubMedGoogle Scholar
  11. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750–758PubMedCrossRefGoogle Scholar
  12. Collins RH Jr, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, Barrett J, Johnson M, Kirk A, Horowitz M, Parker P (2000) Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 26:511–516PubMedCrossRefGoogle Scholar
  13. de Lima M, Couriel D, Shahjahan M, Madden T, Gajewski J, Giralt S, Russell J, Champlin RE, Andersson BS (2002) Allogeneic transplantation for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) using a low-toxicity combination of intravenous (IV) busulfan (Bu) and fludarabine (Flu) + ATG (abstract). Blood 100 (Part l):853a, #3366Google Scholar
  14. Deeg HJ, Storb R, Weiden PL, Raff RF, Sale GE, Atkinson K, Graham TC, Thomas ED (1982) Cyclosporin A and methotrexate in canine marrow transplantation: engraftment, graft-versus-host disease, and induction of tolerance. Transplantation 34:30–35PubMedGoogle Scholar
  15. Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D, Poliquin C, Vanderklish J, Sachs DH, Sykes M, Spitzer TR (2001) Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant 7:604–612PubMedCrossRefGoogle Scholar
  16. Dey BR, McAfee SL, Colby C, Sackstein R, Saidman S, Tarbell N, Sachs DH, Sykes M, Spitzer TR (2002) Comparison of outcomes after transplantation of peripheral blood stem cells (PBSCT) versus bone marrow (BMT) following an identical non-myeloablative conditioning regimen (abstract). Blood 100 (Part l):424a, #1641Google Scholar
  17. Gale RP, Marmont A, Horowitz M, Bortin MM (1989) T cell depletion to prevent GvHD: preliminary univariate analyses of the IBMTR. Bone Marrow Transplant 4(Suppl 2):121Google Scholar
  18. Georges GE, Storb R, Thompson JD, Yu C, Gooley T, Bruno B, Nash RA (2000) Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation. Blood 95:3262–3269PubMedGoogle Scholar
  19. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P, O’Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Körbling M, Keating M, Kantarjian H, Champlin R (1997 a) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531–4536PubMedGoogle Scholar
  20. Giralt S, Gajewski J, Khouri I, Korbling M, Claxton D, Mehra R, Przepiorka D, Andersson B, Talpaz M, Kantarjian H, Champlin R (1997b) Induction of graft-vs-leukemia (GVL) as primary treatment of chronic myelogenous leukemia (CML) (abstract). Blood 90 (Part l):418a, #1857Google Scholar
  21. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przpiorka D, Ueno NT, Molldrem J, Champlin R (2001) Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97:631–637PubMedCrossRefGoogle Scholar
  22. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, Molldrem J, Ueno NT, Donato M, Korbling M, Gajewski J, Alexanian R, Champlin R (2002) Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 30:367–373PubMedCrossRefGoogle Scholar
  23. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM (1988) Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med 108:806–814PubMedGoogle Scholar
  24. Goulmy E (1997) Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy (review). Immunol Rev 157:125–140PubMedCrossRefGoogle Scholar
  25. Hogan WJ, Little M-T, Zellmer E, Friedetzky A, Diaconescu R, Gisburne S, Lee R, Kuhr C, Storb R (2003) Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. Biol Blood Marrow Transplant 9:489–495PubMedCrossRefGoogle Scholar
  26. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H-J, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555–562PubMedGoogle Scholar
  27. Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, Little M-T, Corey L, Storb R (2002 a) Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99:1978–1985PubMedCrossRefGoogle Scholar
  28. Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, Storb R (2002 b) Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 8:512–520PubMedCrossRefGoogle Scholar
  29. Kernan NA, Bordignon C, Heller G, Cunningham I, Castro-Malaspina H, Shank B, Flomenberg N, Burns J, Yang SY, Black P, Collins NH, O’Reilly RJ (1989) Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. Blood 74:2227–2236PubMedGoogle Scholar
  30. Khouri IF, Saliba RM, Giralt SA, Lee M-S, Okoroji G-J, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE (2001) Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98:3595–3599PubMedCrossRefGoogle Scholar
  31. Kolb HJ, Mittermüller J, Clemm Ch, Holler G, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–2465PubMedGoogle Scholar
  32. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermüller J, De Witte T, Holler E, Ansari H (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041–2050PubMedGoogle Scholar
  33. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfueth S, Pettengell R, Marsh JCW, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, Ruiz de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S (2000) In vivo CAMPATH-1H prevents graft-versus-host disease following non-myeloablative stem cell transplantation. Blood 96:2419–2425PubMedGoogle Scholar
  34. Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D, Petersdorf E, McSweeney P, Pulsipher M, Woolfrey A, Chauncey T, Agura E, Heimfeld S, Slattery J, Hegenbart U, Anasetti C, Blume K, Storb R (2003) HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102(6):2021–2030PubMedCrossRefGoogle Scholar
  35. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong R, Masaoka T, Rimm AA, Ringden O, Speck B, Weiner RS, Bortin MM (1991) T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120–2130PubMedGoogle Scholar
  36. Martin PJ, Hansen JA, Buckner CD, Sanders JE, Deeg HJ, Stewart P, Appelbaum FR, Clift R, Fefer A, Witherspoon RP, Kennedy MS, Sullivan KM, Flournoy N, Storb R, Thomas ED (1985) Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 66:664–672PubMedGoogle Scholar
  37. Martino R, Giralt S, Caballero MD, Mackinnon S, Corradini P, Fernandez-Aviles F, San Miguel J, Sierra J (2003) Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica 88:555–560PubMedGoogle Scholar
  38. Mathé G, Amiel JL, Schwarzenberg L, Catton A, Schneider M (1965) Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res 25:1525–1531PubMedGoogle Scholar
  39. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers MED, Georges GE, Grumet FC, Kiem H-P, Torok-Storb B, Yu C, Blume KG, Storb RF (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390–3400PubMedCrossRefGoogle Scholar
  40. Molina AJ, Storb RF (2000) Hematopoietic stem cell transplantation in older adults. In: Rowe JM, Lazarus HM, Carella AM (eds) Handbook of bone marrow transplantation. Martin Dunitz, London, UK, pp 111–137Google Scholar
  41. Morris E, Thomson K, Craddock C, Milligan D, Smith GM, Parker A, Schey S, Winfield D, Chopra R, Littlewood T, Tighe J, Hunter A, Kyriakou C, Kottaridis P, Peggs K, Linch D, Goldstone A, Mackinnon S (2002) Long-term follow-up of an alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for non-Hodgkin’s lymphoma (NHL) (abstract). Blood 100 (Part 1):40a, #139Google Scholar
  42. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R (2000) Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 25:1021–1028PubMedCrossRefGoogle Scholar
  43. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Pönisch W, Anasetti C, Woolfrey A, Little M-T, Blume KG, McSweeney PA, Storb RF (2003) Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101:1620–1629PubMedCrossRefGoogle Scholar
  44. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, Aker M, Naparstek E, Nagler A, Slavin S (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101:441–445PubMedCrossRefGoogle Scholar
  45. Peggs KS, Mackinnon S, Williams CD, D’Sa S, Thuraisundaram D, Kyriakou C, Morris EC, Hale G, Waldmann H, Linch DC, Goldstone AH, Yong K (2003) Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 9:257–265PubMedCrossRefGoogle Scholar
  46. Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang Y-G, Sykes M (1999) Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 5:133–143PubMedCrossRefGoogle Scholar
  47. Petersdorf EW, Gooley TA, Anasetti C, Martin PJ, Smith AG, Mickelson EM, Woolfrey AE, Hansen JA (1998) Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 92:3515–3520PubMedGoogle Scholar
  48. Riddell SR, Greenberg PD (1999) Adoptive immunotherapy with antigen-specific T cells. In: Thomas ED, Blume KG, Forman SJ (eds) Hematopoietic cell transplantation, 2nd edn. Blackwell Science, Boston, pp 327–341Google Scholar
  49. Sandmaier BM, Hegenbart U, Shizuru J, Radich J, Maloney DG, Agura E, Bruno B, Chauncey T, Blume K, Niederwieser D, Storb R (2001 a) Nonmyeloablative hematopoietic stem cell transplantation (HSCT) from HLA-identical siblings for treatment of chronic myelogenous leukemia (CML): induction of molecular remissions (abstract). Blood 98 (Part 2):371b, #5259Google Scholar
  50. Sandmaier BM, Maloney DG, Gooley T, Hegenbart U, Shizuru J, Sahebi F, Chauncey T, Agura E, Bruno B, McSweeney P, Forman S, Blume K, Niederwieser D, Storb R (2001b) Nonmyeloablative hematopoietic stem cell transplants (HSCT) from HLA-matched related donors for patients with hematologic malignancies: clinical results of a TBI-based conditioning regimen (abstract). Blood 98 (Part 1):742a–743a, #3093Google Scholar
  51. Sandmaier BM, Maloney DG, Gooley TA, Shizuru J, Hegenbart U, Sahebi F, Chauncey T, Bruno B, Agura E, McSweeney P, Forman S, Niederwieser D, Blume K, Storb R (2002) Low dose TBI conditioning for hematopoietic stem cell transplants (HSCT) from HLA-matched related donors for patients with hematologic malignancies: influence of fludarabine or cytoreductive autografts on outcome (abstract). Blood 100 (Part 1):145a, #544CrossRefGoogle Scholar
  52. Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, Kroger N, Hensel M, Scheffold C, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W (2002) Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia. Ann Hematol 81(Suppl 2):S47–S48PubMedGoogle Scholar
  53. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R (1995) Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 23:1553–1562PubMedGoogle Scholar
  54. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756–763PubMedGoogle Scholar
  55. Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P, Saidman S, Weymouth DW, Preffer F, Poliquin C, Foley A, Cox B, Andrews D, Sachs DH, Sykes M (2000) Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplantation6:309–320CrossRefGoogle Scholar
  56. Spitzer TR, McAfee SL, Dey BR, Colby C, Hope J, Grossberg H, Preffer F, Saidman S, Shaffer J, Alexander SI, Sachs DH, Sykes M (2002) Ex vivo T-cell depleted non-myeloablative haploidentical transplantation for advanced hematologic malignancy (abstract). Blood 100 (Part 1):638a, #2513Google Scholar
  57. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729–735PubMedGoogle Scholar
  58. Storb R, Raff RF, Appelbaum FR, Graham TC, Schuening FG, Sale G, Pepe M (1989) Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts. Blood 74:1139–1143PubMedGoogle Scholar
  59. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, Leisenring W, Shulman H (1997) Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89:3048–3054PubMedGoogle Scholar
  60. Storb R, Yu C, Barnett T, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, McSweeney P, Seidel K, Georges G, Zaucha JM (1999 a) Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 94:1131–1136PubMedGoogle Scholar
  61. Storb R, Yu C, Zaucha JM, Deeg HJ, Georges G, Kiem H-P, Nash RA, McSweeney PA, Wagner JL (1999 b) Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 94:2523–2529PubMedGoogle Scholar
  62. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, Beatty P, Bensinger W, Berenson R, Bigelow C, Cheever MA, Clift R, Deeg HJ, Doney K, Greenberg P, Hansen JA, Hill R, Loughran T, Martin P, Neiman P, Petersen FB, Sanders J, Singer J, Stewart P, Thomas ED (1989) Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720–1728PubMedGoogle Scholar
  63. Sykes M, Preffer F, McAfee S, Saidman SL, Weymouth D, Andrews DM, Colby C, Sackstein R, Sachs DH, Spitzer TR (1999) Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 353:1755–1759PubMedCrossRefGoogle Scholar
  64. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD (1975) Bone-marrow transplantation. N Engl J Med 292:832–843, 895–902PubMedGoogle Scholar
  65. Thomas ED, Blume KG, Forman SJ (eds) (1999) Hematopoietic cell transplantation, 2nd edn. Blackwell Science, BostonGoogle Scholar
  66. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300:1068–1073PubMedGoogle Scholar
  67. Weiden PL, Flournoy N, Thomas ED, Fefer A, Storb R (1981a) Antitumor effect of marrow transplantation in human recipients of syngeneic or allogeneic grafts. In: Okunewick J, Meredith R (eds) Graft-versus-leukemia in man and animal models. CRC, Boca Raton, pp 11–23Google Scholar
  68. Weiden PL, Storb R, Deeg HJ (1981b) Antitumor effect of marrow transplantation in randomly bred species: studies in dogs with spontaneous lymphoma. In: Okunewick J, Meredith R (eds) Graft-versus-leukemia in man and animal models. CRC, Boca Raton, pp 127–138Google Scholar
  69. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, and the Seattle Marrow Transplant Team (1981c) Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529–1533PubMedGoogle Scholar
  70. Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Gooley T, Storb R (2001) Decreased transfusion requirements for patients receiving non-myeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 98:3584–3588PubMedCrossRefGoogle Scholar
  71. Yu C, Storb R, Mathey B, Deeg HJ, Schuening FG, Graham TC, Seidel K, Burnett R, Wagner JL, Shulman H, Sandmaier BM (1995) DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. Blood 86:4376–4381PubMedGoogle Scholar
  72. Yu C, Seidel K, Nash RA, Deeg HJ, Sandmaier BM, Barsoukov A, Santos E, Storb R (1998) Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 91:2581–2587PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • M. L. Sorror
  • R. Storb
    • 1
  1. 1.Fred Hutchinson Cancer Research CenterSeattleUSA

Personalised recommendations